India will invest 100 billion rupees ($1.1 billion) in biopharmaceutical research over the next five years as part of a broader push to scale up domestic manufacturing, signaling a renewed focus on higher-value drug development.
The funding will be directed toward the research and production of biologics and biosimilar medicines, with the government targeting to position the country as a global biopharma manufacturing hub, Finance Minister
The announcement marks a shift for India’s pharmaceutical industry, where companies have historically spent less on research and development than global peers, focusing instead on lower-value generics ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.
